Histological diagnosis of non-small cell lung cancer (NSCLC) at stage II-III (locally advanced), unresectable/inoperable.
Candidate for radical radiotherapy with concomitant chemotherapy, with or without maintenance Durvalumab.
ECOG performance status ≤2 (or Karnofsky index ≥60).
Ability to communicate adequately with the research team and to complete questionnaires and functional tests.
Signed written informed consent after receiving detailed information about the study.
You may not be if
Decompensated cardiorespiratory comorbidities that contraindicate moderate-intensity physical exercise:
* New York Heart Association (NYHA) class III-IV congestive heart failure or unstable angina.
* Recent myocardial infarction (\<6 months) or uncontrolled arrhythmias.
* Very severe chronic obstructive pulmonary disease (COPD) GOLD IV with recent exacerbations, permanent home oxygen therapy, or severe pulmonary hypertension.
Severe physical or neurological limitations that prevent exercise.
Absolute medical contraindications to inspiratory muscle training: unresolved pneumothorax, recent thoracic surgery (\<4 weeks), or active hemoptysis.
Refusal or inability to understand/follow the program instructions (e.g., severe cognitive impairment, insurmountable language barrier).
